Diffusion and Protein Corona Formation of Lipid-Based Nanoparticles in the Vitreous Humor: Profiling and Pharmacokinetic Considerations.


Journal

Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791

Informations de publication

Date de publication:
01 02 2021
Historique:
pubmed: 26 6 2020
medline: 12 10 2021
entrez: 26 6 2020
Statut: ppublish

Résumé

The vitreous humor is the first barrier encountered by intravitreally injected nanoparticles. Lipid-based nanoparticles in the vitreous are studied by evaluating their diffusion with single-particle tracking technology and by characterizing their protein coronae with surface plasmon resonance and high-resolution proteomics. Single-particle tracking results indicate that the vitreal mobility of the formulations is dependent on their charge. Anionic and neutral formulations are mobile, whereas larger (>200 nm) neutral particles have restricted diffusion, and cationic particles are immobilized in the vitreous. PEGylation increases the mobility of cationic and larger neutral formulations but does not affect anionic and smaller neutral particles. Convection has a significant role in the pharmacokinetics of nanoparticles, whereas diffusion drives the transport of antibodies. Surface plasmon resonance studies determine that the vitreal corona of anionic formulations is sparse. Proteomics data reveals 76 differentially abundant proteins, whose enrichment is specific to either the hard or the soft corona. PEGylation does not affect protein enrichment. This suggests that protein-specific rather than formulation-specific factors are drivers of protein adsorption on nanoparticles in the vitreous. In summary, our findings contribute to understanding the pharmacokinetics of nanoparticles in the vitreous and help advance the development of nanoparticle-based treatments for eye diseases.

Identifiants

pubmed: 32584047
doi: 10.1021/acs.molpharmaceut.0c00411
pmc: PMC7856631
doi:

Substances chimiques

Liposomes 0
Ophthalmic Solutions 0
Protein Corona 0
Polyethylene Glycols 3WJQ0SDW1A

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

699-713

Références

Prog Retin Eye Res. 2017 Mar;57:134-185
pubmed: 28028001
Ophthalmology. 2008 Oct;115(10):1750-5, 1755.e1
pubmed: 18708261
Invest Ophthalmol Vis Sci. 2014 Jan 29;55(1):567-73
pubmed: 24398088
Ophthalmology. 2007 May;114(5):855-9
pubmed: 17467524
Biochem Soc Trans. 2004 Aug;32(Pt 4):636-9
pubmed: 15270695
Anal Chem. 2016 Oct 18;88(20):9980-9988
pubmed: 27644331
J Ocul Pharmacol Ther. 2017 Mar;33(2):115-122
pubmed: 28055308
Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3553-61
pubmed: 16186333
Eye (Lond). 1987;1 ( Pt 2):254-62
pubmed: 3308528
Arch Histol Cytol. 2002 Aug;65(3):263-8
pubmed: 12389665
Drug Discov Today. 2019 Aug;24(8):1551-1563
pubmed: 31319151
J Control Release. 2019 Aug 10;307:1-15
pubmed: 31170467
Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6501-5
pubmed: 26447985
Biochimie. 2002 Dec;84(12):1237-43
pubmed: 12628301
Proteomics. 2018 Mar;18(5-6):e1700394
pubmed: 29356342
Front Immunol. 2016 Apr 25;7:159
pubmed: 27199984
Chem Soc Rev. 2012 Apr 7;41(7):2780-99
pubmed: 22086677
Invest Ophthalmol Vis Sci. 2015 Nov;56(12):7036-42
pubmed: 26529037
J Proteome Res. 2015 Dec 4;14(12):5131-43
pubmed: 26490944
PLoS One. 2015 May 28;10(5):e0127567
pubmed: 26020955
Invest Ophthalmol Vis Sci. 1987 May;28(5):893-900
pubmed: 3106257
J Control Release. 2013 Apr 10;167(1):76-84
pubmed: 23369761
PLoS One. 2016 Apr 18;11(4):e0153560
pubmed: 27089221
J Mol Biol. 1982 May 5;157(1):105-32
pubmed: 7108955
Eur J Pharm Biopharm. 2015 Sep;95(Pt B):407-17
pubmed: 26032291
Biochimie. 2002 Apr;84(4):295-302
pubmed: 12106907
Nanoscale. 2020 Jan 23;12(3):1728-1741
pubmed: 31894806
Nanoscale. 2017 Jun 29;9(25):8858-8870
pubmed: 28632260
Biomaterials. 2016 Dec;109:23-31
pubmed: 27648757
J Control Release. 2018 Aug 28;284:213-223
pubmed: 29964133
Exp Eye Res. 1981 Apr;32(4):381-8
pubmed: 7238623
PLoS One. 2013 Nov 29;8(11):e82140
pubmed: 24312404
Mol Pharm. 2018 Jun 4;15(6):2174-2179
pubmed: 29648838
Sci Rep. 2018 Jan 17;8(1):982
pubmed: 29343691
ACS Nano. 2019 Jul 23;13(7):8023-8034
pubmed: 31268684
Adv Mater. 2019 Jan;31(4):e1803335
pubmed: 30488990
Nanomedicine (Lond). 2013 Dec;8(12):1955-68
pubmed: 23438206
Mol Pharm. 2016 Sep 6;13(9):2941-50
pubmed: 26726925
Eye (Lond). 2008 Oct;22(10):1214-22
pubmed: 18309340
Vision Res. 2008 Apr;48(9):1137-43
pubmed: 18346775
Langmuir. 2011 Jun 21;27(12):7788-98
pubmed: 21604684
J Control Release. 2016 Dec 28;244(Pt B):157-166
pubmed: 27565215
J Biomed Mater Res A. 2008 Dec 1;87(3):656-65
pubmed: 18189301
Surv Ophthalmol. 2011 Jul-Aug;56(4):300-23
pubmed: 21601902
J Cell Biol. 2014 Jan 20;204(2):231-45
pubmed: 24446482
Mol Cell Proteomics. 2014 Sep;13(9):2513-26
pubmed: 24942700
Eye (Lond). 2002 Jul;16(4):429-39
pubmed: 12101450
Retina. 2008 Jan;28(1):150-3
pubmed: 18185153
Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4807-13
pubmed: 19324856
Biophys J. 2015 Nov 17;109(10):2171-81
pubmed: 26588575
Nat Nanotechnol. 2017 Jul;12(6):523-529
pubmed: 28436961
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
J Control Release. 2016 Aug 10;235:337-351
pubmed: 27297779
Exp Eye Res. 1991 Jan;52(1):27-39
pubmed: 1714398
Proteomics. 2013 Aug;13(16):2500-11
pubmed: 23749747
Am J Ophthalmol. 2008 Oct;146(4):508-12
pubmed: 18635152
Retina. 2013 May;33(5):946-52
pubmed: 23407351
Proteome Sci. 2013 May 20;11(1):22
pubmed: 23688336
Chem Phys Lipids. 2005 Jun;135(2):117-29
pubmed: 15921973
Pharm Res. 2003 Apr;20(4):576-83
pubmed: 12739764
Biophys J. 2004 Jul;87(1):553-61
pubmed: 15240488
Mol Pharm. 2016 Jun 6;13(6):2095-107
pubmed: 27097108

Auteurs

Shirin Tavakoli (S)

Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, 00014, Helsinki, Finland.

Otto Kalevi Kari (OK)

Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, 00014, Helsinki, Finland.

Tiina Turunen (T)

Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, 00014, Helsinki, Finland.

Tatu Lajunen (T)

Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, 00014, Helsinki, Finland.

Mechthild Schmitt (M)

Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, 00014, Helsinki, Finland.

Julia Lehtinen (J)

Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, 00014, Helsinki, Finland.

Fumitaka Tasaka (F)

Pharmaceutics & Pharmacology Department, Global R&D, Santen Pharmaceutical Co., Ltd., 8916-16 Takayama-cho, Ikoma, Nara 630-0101, Japan.

Petteri Parkkila (P)

Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, 00014, Helsinki, Finland.

Joseph Ndika (J)

Human Microbiome Research, Faculty of Medicine, University of Helsinki, P.O. Box 21, 00290 Helsinki, Finland.

Tapani Viitala (T)

Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, 00014, Helsinki, Finland.

Harri Alenius (H)

Human Microbiome Research, Faculty of Medicine, University of Helsinki, P.O. Box 21, 00290 Helsinki, Finland.
Institute of Environmental Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden.

Arto Urtti (A)

Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, 00014, Helsinki, Finland.
Institute of Chemistry, St. Petersburg State University, Petergof, Universitetskii pr. 26, 198504 St. Petersburg, Russia.
School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Yliopistonranta 1, 70210 Kuopio, Finland.

Astrid Subrizi (A)

School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Yliopistonranta 1, 70210 Kuopio, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH